Cited 10 times in
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 허수진 | - |
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 임선민 | - |
dc.contributor.author | 정인경 | - |
dc.contributor.author | 이충근 | - |
dc.date.accessioned | 2017-10-26T07:32:00Z | - |
dc.date.available | 2017-10-26T07:32:00Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152155 | - |
dc.description.abstract | OBJECTIVES: To evaluate whether the selection of first-line chemotherapy based on ERCC1 and RRM1 mRNA expression levels would improve clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Eligible patients were randomly assigned 1:1 to the experimental and control arms; the experimental arm received gemcitabine/carboplatin (GC) if ERCC1 and RRM1 expression was low, gemcitabine/vinorelbine (GV) if ERCC1 was high and RRM1 was low, docetaxel/carboplatin (DC) if ERCC1 was low and RRM1 was high, and docetaxel/vinorelbine (DV) if both were high. In the control arm, patients received DC. RESULTS: This study was prematurely terminated after the futility analysis of 43 progression-free survival (PFS) events. A total of 55 patients (n = 26 in the experimental arm, n = 29 in the control arm) were evaluable for efficacy and toxicity. Nineteen (73.1%) patients were assigned to receive GC, 0 (0.0%) to GV, 4 (15.4%) to DC, and 3 (11.5%) to DV in the experimental arm. The overall response rates were 42.3 and 48.3% in the experimental and control arms, respectively, which were not statistically different (P = 0.657). The median PFS was 5.2 months in the experimental arm and 5.4 months in the control arm (P = 0.286). The median overall survival was 17.4 months in the experimental arm and 12.6 months in the control arm (P = 0.638). The occurrence of grade 3 or higher neutropenia (69.2 vs. 93.1%, P = 0.035) and febrile neutropenia (3.8 vs. 24.1%, P = 0.054) was more common in the control arm. CONCLUSION: ERCC1 and RRM1 mRNA expression-based chemotherapy did not improve clinical outcomes in advanced NSCLC (NCT01648517). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer Verlag | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/pharmacology | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carboplatin/administration & dosage | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.MESH | DNA-Binding Proteins/genetics* | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Endonucleases/genetics* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/genetics | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | RNA, Messenger/metabolism | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Suppressor Proteins/genetics* | - |
dc.subject.MESH | Vinblastine/administration & dosage | - |
dc.subject.MESH | Vinblastine/analogs & derivatives | - |
dc.subject.MESH | Young Adult | - |
dc.title | A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.publisher.location | Germany | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Su Jin Heo | - |
dc.contributor.googleauthor | Inkyung Jung | - |
dc.contributor.googleauthor | Choong-kun Lee | - |
dc.contributor.googleauthor | Jee Hung Kim | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Yong Wha Moon | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.contributor.googleauthor | Jaeheon Jeong | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1007/s00280-016-2968-z | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04355 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A03369 | - |
dc.contributor.localId | A03693 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 26811178 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00280-016-2968-z | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | ERCC1 | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | RRM1 | - |
dc.subject.keyword | mRNA expression | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Heo, Su Jin | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Lim, Sun Min | - |
dc.contributor.alternativeName | Jung, In Kyung | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Heo, Su Jin | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Lim, Sun Min | - |
dc.contributor.affiliatedAuthor | Jung, In Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.citation.volume | 77 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 539 | - |
dc.citation.endPage | 548 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.77(3) : 539-548, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46934 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.